Purpose Huntington's disease (HD) is an autosomal dominant neurodegenerative disease associated with motor, behavioral, and cognitive deficits. The hallmark symptom of HD, chorea, is often the focus of HD clinical trials. Unfortunately, there are no self-reported measures of chorea. To address this shortcoming, we developed a new measure of chorea for use in HD, HDQLIFE Chorea. Methods Qualitative data and literature reviews were conducted to develop an initial item pool of 141 chorea items. An iterative process, including cognitive interviews, expert review, translatability review, and literacy review, was used to refine this item pool to 64 items. These 64 items were field tested in 507 individuals with prodromal and/or manifest HD. Exploratory and confirmatory factor analyses (EFA and CFA, respectively) were conducted to identify a unidimensional set of items. Then, an item response theory graded response model (GRM) and differential item functioning analyses were conducted to select the final items for inclusion in this measure. Results EFA and CFA supported the retention of 34 chorea items. GRM and DIF supported the retention of all of these items in the final measure. GRM calibration data were used to inform the selection of a 6-item, static short form and to program the HDQLIFE Chorea computer adaptive test (CAT). CAT simulation analyses indicated a 0.99 correlation between the CAT scores and the full item bank. Conclusions The new HDQLIFE Chorea CAT and corresponding 6-item short form were developed using established rigorous measurement development standards; this is the first self-reported measure developed to evaluate the impact of chorea on HRQOL in HD. This development work indicates that these measures have strong psychometric properties; future work is needed to establish testretest reliability and responsiveness to change.
Introduction
Huntington's disease (HD) is an autosomal dominantly inherited neurodegenerative disease resulting from a trinucleotide expansion of cytosine-adenosine-guanine (CAG) in the HTT gene at 4p16.3 [1] . While HD involves cognitive and behavioral decline, the hallmark symptom of HD is chorea. Chorea is an abnormal involuntary movement defined as irregular, flowing movements of the face, trunk, and limbs of varying amplitude [2] . Age at onset of motor symptoms varies, with average age around 40 years, and involves progressive decline and premature death approximately 15-20 years later [3] . When the motor signs of HD begin, chorea may be subtle. As the disease progresses, chorea may become larger in amplitude and frequency, causing injury and impairing physical functioning. In addition, chorea, in combination with the other motor impairments associated with HD, is associated with increased injuries and falls [2, 4] and increases the risk of nursing home placement [5] . Choreic movements are often stigmatizing, as they are commonly mistaken for drunkenness [6] . Importantly, motor impairment and chorea are associated with lower self-reported HRQOL [7] [8] [9] [10] . Although there is no cure for HD, medications for chorea can temporarily reduce the frequency and amplitude of movements. However, side effects from commonly used medications such as somnolence, akathisia, dysphagia, gait issues, and apathy may negatively impact HRQOL [2] . Unfortunately, there are no measures to evaluate the impact of chorea on HRQOL.
Assessment of motor symptoms in HD is typically conducted by a trained motor rater using the Unified Huntington Disease Rating Scale (UHDRS) Motor scale [11] . The UHDRS Motor scale captures several aspects of the neurological examination that are often compromised in HD (i.e., voluntary and involuntary movements, eye movements, gait, and balance). Scores reflect a Total Motor Score (TMS) as well as a diagnostic confidence level (DCL) based on motor rater judgment of whether motor signs demonstrate unequivocal signs of HD. While the DCL is a reliable measure of motor diagnosis and the TMS is a good prognostic indicator of onset within 5 years of diagnosis [12] , the TMS is a clinician-rated scale that does not include subjective input from the individual with HD. Thus, the TMS does not evaluate the impact of chorea on HRQOL. In fact, there are no existing patient-reported outcome (PRO) measures that examine chorea. This gap in measurement is especially problematic given the Food and Drug Administration (FDA) recommendation to include patient-reported outcome (PRO) measures in clinical trials in order to support claims of a treatment's efficacy in improving HRQOL [13] .
To this end, recent efforts have been devoted to developing state-of-the-art PRO assessments through the NeuroQoL [14, 15] and patient-reported outcome measurement information system (PROMIS) [16, 17] HRQOL measurement systems. These measurement systems were developed to create standardized outcome measures for use in clinical trials that are based on patient report for persons with chronic diseases and neurological disorders [16, 18] . Because HD involves the unique motor impairment, chorea, it is important that PROs used in HD clinical trials include a HRQOL PRO related to chorea. Therefore, the purpose of this study was to develop a PRO measure of self-reported HRQOL related to chorea using established PROMIS methodology [19] .
Methods

Participants
Five hundred and seven individuals with prodromal HD (CAG C 36, but did not yet have an HD clinical diagnosis) and/or manifest HD (had clinical diagnosis of HD) were included in our sample. Participants had to be at least 18 years of age and able to read and comprehend English, and have the ability to provide informed consent. Participants were recruited from specialized HD treatment centers at the University of Michigan, the University of Iowa, the University of California-Los Angeles, Indiana University, Johns Hopkins University, Rutgers University, Struthers Parkinson's Center, and Washington University. Participants were also recruited through electronic medical records [20] , the National Research Roster for Huntington's Disease, articles/advertisements in HD-specific newsletters and Web sites, and the Predict-HD study [21] .
HDQLIFE Chorea item pool
We began with an initial pool of 141 questions that were designed to evaluate how chorea impacts function and HRQOL using the same methodology used by the NeuroQoL and PROMIS [19] . Specific item content was based on focus group discussion among individuals at risk of HD, those with prodromal HD, individuals with manifest HD, non-professional caregivers of individuals with HD (e.g., family members), and professionals working with individuals with HD (n = 6 groups with symptomatic HD; n = 5 with individuals at risk of or prodromal for HD; n = 3 non-clinical caregivers; n = 2 groups with HD clinicians) [10] . Items were further refined via results from expert review, evaluation of item literacy level, and patient cognitive review to ensure adequate content coverage, appropriate reading levels, and comprehension level. The final item pool included 64 questions designed to evaluate how chorea affects HRQOL [22] .
Clinician-rated measures
Several measures from the UHDRS [11] were administered to all participants. This included the Total Functional Capacity (TFC) scale [23] which is a 5-item clinician-rated measure that provides an index of total functional capacity. Specifically, these five items evaluate day-to-day functioning across the domains of occupation, finances, domestic chores, activities of daily living, and care level.
Scores range from 0 (lowest level of functioning) to 13 (highest level of functioning). In this study, TFC scores were used to classify participants with an HD diagnosis as either early stage (sum scores of 7-13) or later stage (sum scores of 0-6). In addition, participants completed the UHDRS motor examination, which includes 15 clinicianrated items designed to evaluate oculomotor function, dysarthria, motor task sequencing, rhythmic tapping, chorea, dystonia, gait, and postural stability. Scores range from 0 (no motor difficulties) to 120 (greater motor difficulties).
Statistical analyses
All analyses were conducted according to the established PROMIS measurement development guidelines [19] . We used factor analysis to examine the unidimensionality of items. We first randomly divided the sample into two datasets: one for exploratory factor analysis (EFA; n = 254) and the other for confirmatory factor analysis (CFA; n = 253). We used EFA with a PROMAX rotation to determine the number of factors within the item pool using the following criteria: (1) eigenvalues [1 and (2) the number of factors before the break in the scree plot. Item loadings were used to determine items and their associated factor (criterion [ 0.3). CFA was conducted to confirm the factor structure from EFA using the following criteria: (1) comparative fit index (CFI) [ 0.90, (2) root mean square error of approximation (RMSEA) \0.1 [24] [25] [26] [27] , and (3) residual correlations \0.15 [28] [29] [30] . EFA and CFA analyses were conducted using MPLUS 6.11 [31] .
Parameters of items that met unidimensional criteria were estimated by using an IRT model-Samejima's graded response model (GRM) [32] . Item parameters were used to estimate information functions at the level of individual items and at the level of the entire item bank and to characterize the precision of items and the overall scale on the measurement continuum. Differential item functioning (DIF) was used to evaluate the stability of an item's measurement properties across subgroups within certain variables using IRT-scaled score-based ordinal logistic regression [33] ; these analyses were implemented using LORDIF freeware [34] . Variables used for this study were gender, age (B40 vs. [40; B50 vs. [50 years), and education (high school graduate or less vs. [high school). Items that showed significant DIF (criterion: p \ 0.01) of non-negligible magnitude (R2 [ 0.02) in more than one comparison were candidates for removal from the chorea measure due to potential measurement bias. IRT-scaled scores were generated using the GRM and then converted into a standardized score utilizing a t metric (mean = 50, SD = 10); these standardized scores were used for the rest of the analyses. IRTPRO 2.1 software was used to conduct these analyses [35] . CAT simulations were conducted using Firestar CAT simulation software [36] .
Preliminary validation data
Pearson's correlations between the new HDQLIFE Chorea measure and the UHDRS Total Motor Score were calculated to examine convergent validity. To demonstrate adequate convergent validity, correlations between these measures should be moderate to large (r = 0.5-0.8) [37] . A univariate analysis was conducted to determine whether there were significant differences among the HD groups (prodromal vs. early-, vs. late-stage HD) on HDQLIFE Chorea. Tukey's honestly significant difference (HSD) post hoc analyses were used to identify significant between groups effects. We expect significant differences among the three groups with prodromal HD reporting less chorearelated functional difficulties than either early-or late-stage HD participants, and early-stage HD participants reporting less chorea-related functional difficulties than late-stage HD participants.
Results
Participants
A total of 507 individuals with prodromal and/or manifest HD participated: 196 individuals had prodromal HD (CAG C36, but did not yet have an HD clinical diagnosis), 193 had early-stage HD (sum scores of 7-13 on the TFC), 117 had later-stage HD (sum scores of 0-6 on the TFC), and one individual was not classifiable (due to missing information); see Table 1 for a summary of demographic information. The mean age was 49.01 years (SD = 13.21; range 18-81), and the majority of participants were Caucasian (96.4 %) and female (59.2 %). Average education was 15.06 years (SD = 2.88; range 4-26). As expected, there were significant group differences for age (as symptoms are progressive with age), F (2, 503) = 47.360, p \ 0.0001. Prodromal participants (M = 42.60, SD = 12.04) were significantly younger than early-stage (M = 51.91, SD = 12.41) and late-stage participants (M = 55.07, SD = 11.89), and the early-stage participants were younger than the late-stage individuals. There were no group differences for gender, V 2 (2, N = 506) = 3.193, p = 0.20, or ethnicity, V 2 (2, N = 486) = 4.300, p = 0.12. There were very small group differences for education, F (2, 501) = 14.781, p \ 0.0001; early-stage HD (M = 14.74, SD = 2.78) and late-stage HD (M = 14.22, SD = 2.62) had 1-1.5 years less education relative to prodromal HD participants (M = 15.88 years, SD = 2.94).
EFA and CFA findings
EFA findings suggested that the data could be explained by five factors ( Table 2) . Factor 1 included 31 items that involve specific impact of chorea on various aspects of physical and social functioning. Factor 2 included 30 items that examined the impact of chorea on physical, social, and emotional functioning (11 items had substantial cross-loadings on Factor 1). Factor 3 consisted of 13 items concerning tremors and shaking (2 items crossloaded on Factor 1; 2 items cross-loaded on Factor 2; 1 item cross-loaded on Factors 2 and 4). Factor 3 was not included for further consideration, as these items are more indicative of parkinsonism movements (i.e., tremors and shakiness) than chorea (i.e., fluid and dance-like movements). Factor 4 consisted of 16 items concerning chorea frequency and severity and the impact of chorea on physical and emotional functioning (4 items cross-loaded on Factor 1; 8 items cross-loaded on Factor 2; 1 item cross-loaded on Factor 3). Factor 5 consisted of 2 items involving the impact of chorea on driving (1 item crossloaded on Factor 1). Factor 5 was not included for further consideration as two items are not appropriate for consideration as a scale.
Conceptually, Factors 1, 2, and 4 had substantial overlap (all three factors included items that reflected the impact/effect that chorea had on overall functioning). Thus, we focused on Factor 1 (which included the most items and accounted for the largest amount of variance), and retained items from Factors 2 and 4 that reflected the impact that chorea had on either physical or social functioning. Thus, 40 items were retained for further consideration in the CFA (we deleted 7 items from Factors 2 and/or 4 that reflected emotional functioning, 4 items from Factors 2 and 4 that had higher cross-loadings on Factor 3 or 5, and 5 items from Factor 4 that reflected chorea severity). The initial CFA with the remaining 40 items revealed that 6 items had large residual correlations. These 6 items were removed in a subsequent confirmatory factor analysis with the 34 remaining items. Results from that analysis indicated that all 34 items examined fit the data well; CFI = 0.98, TLI = 0.98, RMSEA = 0.07, all r 2 [ 0.03. In addition, all residual correlations were \0.15. Cronbach's alpha for this scale was 0.98, and all item-total correlations were [0.7.
IRT analyses
IRT parameter estimates for the 34 items indicated slopes ranging from 2.64 to 6.21 and thresholds ranging from -0.39 to 2.13 (Table 3) . Information was good for scaled scores between -0.6 and ?2.7 (see Fig. 1 for the scale information function), and the marginal reliability was 0.88. A 6-item calibrated short form was then selected using item calibration statistics (e.g., slope, item characteristic curves, item information, and average item difficulty), as well as input on clinical characteristics (e.g., items were selected that represent different clinical components of chorea difficulties). Specifically, we balanced the psychometric considerations with clinical content to ensure representativeness of the items that were selected for the short form (see Table 3 ). We also examined differential item functioning (DIF) to ensure that selected items do not perform differently for different subgroups of participants when they should not (i.e., with relation to gender, age, and education). Specifically, items did not demonstrate DIF for age (\50 vs. C50 and \40 vs. C40), gender (male vs. female), or education (some college and lower vs. college degree and higher).
Short-form scores
The IRT-scaled scores (thetas) were converted into a standardized score utilizing a t metric (mean = 50, SD = 10); scores are based on HD sample means. Table 4 shows a summed score conversion table. The short-form scores had a marginal reliability of 0.78.
CAT simulation
The correlation between the CAT scores and the full item bank was 0.99, indicating that simulated CAT administration can produce results that are very similar to those obtained with administration of the entire 34-item set. Figure 2 shows the number of CAT items used for different scale scores in standard deviation units: At -1 SD units, the CAT always used all 34 items in the item bank; from ?0.3 to ?2.0 SD units, the CAT always used the minimum number of 4 items in the item bank; and at 3 SD units, the CAT used all 34 items in the item bank. Thus, the CAT simulation indicates that fewer items were needed to estimate scores for individuals with greater chorea than for individuals with less chorea.
Preliminary validation data
There was a significant positive correlation between HDQLIFE Chorea and the UHDRS Total Motor Score (r = 0.64, p \ 0.0001) providing support for convergent validity. Univariate analysis also indicated significant group differences for HDQLIFE Chorea, F (2, 489) = 159.2, The HDQLIFE Chorea item bank has several strengths. First, it was developed using well-established, state-of-theart methodology [19] and meets established psychometric standards; it is a homogenous item set with excellent reliability. Items are also devoid of age, gender, and education bias. In addition, there is preliminary support for both convergent and known-groups validity. The HDQLIFE is also the first PRO system to include an assessment of chorea, and it is also the first time that CAT technology has been used to assess HRQOL in HD [22, 38, 39] . CAT offers several advantages to traditional test administration format in that only the most relevant items are administered to each participant, minimizing participant burden without sacrificing overall sensitivity. Furthermore, the corresponding static short form offers a more traditional test administration format, but since each item was developed and selected using IRT, each individual test item provides meaningful information. Thus, even if a participant only answers a single question, a meaningful score can still be derived (albeit the standard error of this score will be large). Finally, as mentioned above, the scoring is based on a t metric, which allows for straightforward interpretation of scores that are more than 1 SD above the mean (i.e., 60 or above).
While this study exhibits several strengths, we also acknowledge a number of weaknesses. First, although CAT administration is generally more efficient than traditional administration approaches, responders at either extreme end of the chorea spectrum (i.e., either very significant chorea or no chorea) may require more items to estimate a score. Furthermore, inconsistent responding will also require the administration of more items to estimate a score. Regardless, CAT simulation data suggest that the CAT performs well for individuals with chorea scale scores between -0.4 and 2.3 (i.e., less than 10 items are administered). More work using prospective data is needed to confirm this. While rates for race/ethnicity of this HD sample were consistent with established prevalence rates [40] [41] [42] [43] and other large HD research cohorts [44] [45] [46] , this sample was primarily Caucasian, and therefore, generalizability to other race/ethnic groups is uncertain. Furthermore, additional work is needed to establish test-retest reliability and responsiveness to change data for this measure. Future work is also needed to examine the relationship of this new measure with more general self-reported measures of motor functioning.
Regardless, this is the first HD-specific PRO measure of chorea, and it is the first time that CAT has been used to evaluate HRQOL (or any other construct) in HD. This new PRO is a potential candidate for inclusion in HD clinical trials that target treatment of chorea. This is especially important given that the only medications that are currently labeled for treatment of HD target the treatment of chorea.
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